KRKA, d. d., Novo mesto

Revocation of partial judgement and suspension of patent infringement procedure for ZYLLT in Serbia

On 3 April 2007, Krka Farma d. o. o., Novi Sad received the judgement of the Higher Commercial Court in Belgrade, by which the higher court invalidated the partial judgement of the Commercial Court in Novi Sad from 31 October 2006, by which the commercial court banned the import and sale of product ZYLLT (clopidogrel) in Serbia by Krka, d. d., Novo mesto (hereafter: Krka) and its subsidiary Krka Farma d. o. o., Novi Sad due to the alleged infringement of the Sanofi Aventis patent relating to the clopidogrel active pharmaceutical ingredient in hydrogen sulphate salt form.

Subsequently, the Commercial Court in Novi Sad has issued the decision to suspend the procedure for assessing the alleged infringement of the Sanofi Aventis patent covering clopidogrel active pharmaceutical ingredient in Serbia until the final resolution regarding the validity of the Sanofi Aventis patent. Krka and Krka Farma d. o. o., Novi Sad are claiming that the patent protection of clopidogrel active pharmaceutical ingredient in Serbia was awarded contrary to the provisions of the patent law in force at that time.

Consequently, Krka and Krka Farma d. o. o., Novi Sad can market and sell Zyllt in Serbia.

Krka has informed the public about this dispute by public releases on 6 June 2006, 5 July 2006, 2 November 2006, 23 November 2006 and 12 December 2007.

Date: 5. 4. 2007